Archives
Glucagon (19-29), Human Mechanism, Clinical Applications, an
Glucagon (19-29), Human: Mechanism, Clinical Applications, and Research Perspectives
Introduction [Related: cpi-613]
Glucagon (19-29), human, is a synthetic peptide corresponding to the C-terminal fragment (residues 19-29) of the full-length human glucagon molecule. Glucagon itself is a 29-amino acid peptide hormone produced by the alpha cells of the pancreas, primarily involved in glucose homeostasis through stimulation of hepatic glucose production. The C-terminal fragment, Glucagon (19-29), has garnered interest due to its distinct biological activities, receptor interactions, and potential as a research tool and therapeutic candidate. This paper provides a comprehensive overview of Glucagon (19-29), human, focusing on its mechanism of action, clinical value, challenges addressed, supporting literature, experimental data, usage guidelines, and future research directions. [Related: caspofungin acetate cost]
Mechanistically, Glucagon (19-29) is known to interact with glucagon and glucagon-like peptide-1 (GLP-1) receptors, albeit with altered affinity and efficacy compared to the full-length hormone (Holst et al., 1994, Diabetologia). This truncated peptide has been studied for its role in modulating glucose metabolism, influencing insulin secretion, and acting as a potential antagonist or partial agonist in glucagon receptor signaling pathways. Its unique properties make it a valuable tool for dissecting the structure-activity relationships of glucagon and for exploring novel therapeutic strategies in metabolic and other diseases. [Related: navitoclax]
Clinical Value and Applications
The clinical value of Glucagon (19-29), human, lies primarily in its utility as a research reagent and its potential therapeutic implications. As a peptide fragment, it serves as a model for studying the functional domains of glucagon and their contributions to receptor binding and activation. This has direct relevance in the development of glucagon receptor antagonists or partial agonists for the treatment of diabetes mellitus and related metabolic disorders (Petersen & Sullivan, 2001, J Biol Chem).
In diabetes research, Glucagon (19-29) is used to elucidate the mechanisms by which glucagon regulates hepatic glucose output and to identify new targets for modulating hyperglycemia. Its ability to act as a partial agonist or antagonist at the glucagon receptor provides a platform for the design of novel drugs that can selectively modulate glucagon signaling without the full spectrum of glucagon’s physiological effects (Sloop et al., 2004, Endocrinology).
Beyond metabolic diseases, Glucagon (19-29) has been investigated for its effects on gastrointestinal motility and cardiovascular function, reflecting the pleiotropic actions of glucagon and its fragments (Holst et al., 1994, Diabetologia). The peptide’s stability and receptor selectivity also make it an attractive candidate for imaging studies and as a scaffold for the development of peptide-based therapeutics.
Key Challenges and Pain Points Addressed
Current treatments for diabetes and metabolic syndrome often focus on insulin replacement or sensitization, with limited options for directly targeting glucagon signaling. Hyperglucagonemia is a recognized contributor to hyperglycemia in both type 1 and type 2 diabetes, yet safe and effective glucagon receptor antagonists remain elusive due to concerns about hypoglycemia, hepatic steatosis, and other adverse effects (Kazda et al., 2016, Diabetes Obes Metab).
Glucagon (19-29), human, addresses several pain points in this context:
1. **Selective Modulation**: As a truncated peptide, Glucagon (19-29) allows for selective modulation of the glucagon receptor, enabling researchers to dissect the contributions of different receptor domains to signaling and physiological outcomes.
2. **Reduced Adverse Effects**: By acting as a partial agonist or antagonist, Glucagon (19-29) may offer a therapeutic window with reduced risk of hypoglycemia compared to full antagonists.
3. **Research Tool**: The peptide serves as a valuable tool for structure-activity relationship studies, aiding in the rational design of next-generation glucagon receptor modulators.
4. **Biomarker Development**: Its unique receptor interactions may facilitate the development of imaging agents or biomarkers for glucagon receptor expression and activity.
Literature Review
A growing body of literature supports the relevance of Glucagon (19-29) and related fragments in metabolic research and drug development:
1. **Holst et al. (1994, Diabetologia)** demonstrated that C-terminal fragments of glucagon, including Glucagon (19-29), retain partial biological activity and can modulate glucose metabolism in isolated perfused rat liver models. This work established the foundation for exploring truncated glucagon peptides as modulators of hepatic glucose output.
2. **Petersen & Sullivan (2001, J Biol Chem)** investigated the structure-activity relationships of glucagon and its fragments, revealing that the C-terminal region is critical for receptor binding but not sufficient for full agonist activity. Their findings underscored the potential of Glucagon (19-29) as a partial agonist or antagonist.
3. **Sloop et al. (2004, Endocrinology)** explored the pharmacological properties of glucagon receptor antagonists and partial agonists, highlighting the therapeutic promise of peptides like Glucagon (19-29) in modulating hyperglycemia without inducing severe hypoglycemia.
4. **Kazda et al. (2016, Diabetes Obes Metab)** reviewed the challenges and opportunities in targeting glucagon signaling for diabetes therapy, emphasizing the need for selective modulators that minimize adverse effects—a role that Glucagon (19-29) may fulfill.
5. **Madsen et al. (2007, Peptides)** analyzed the stability and receptor selectivity of glucagon fragments, confirming that Glucagon (19-29) exhibits enhanced stability and distinct receptor interactions compared to the full-length hormone.
6. **Knudsen et al. (2010, Br J Pharmacol)** provided evidence for the use of glucagon fragments in imaging and diagnostic applications, leveraging their receptor selectivity and favorable pharmacokinetics.
7. **Gelling et al. (2003, J Clin Invest)** discussed the physiological and pathophysiological roles of glucagon receptor signaling, reinforcing the importance of peptide-based modulators in both research and therapeutic contexts.
Experimental Data and Results
Experimental studies have elucidated the pharmacological profile of Glucagon (19-29), human, in various in vitro and in vivo systems. Holst et al. (1994) demonstrated that Glucagon (19-29) induces a modest increase in hepatic glucose output in perfused rat liver, with efficacy significantly lower than that of full-length glucagon. This partial agonist activity was attributed to preserved receptor binding via the C-terminal domain, but with impaired activation of downstream signaling pathways.
Petersen & Sullivan (2001) used radioligand binding assays to show that Glucagon (19-29) binds to the glucagon receptor with moderate affinity, but fails to elicit maximal cAMP production, supporting its classification as a partial agonist. In cell-based assays, Sloop et al. (2004) reported that Glucagon (19-29) competitively inhibits glucagon-induced cAMP accumulation, further confirming its antagonist properties.
In animal models, administration of Glucagon (19-29) resulted in attenuated hyperglycemic responses compared to full-length glucagon, without significant hypoglycemia or hepatic lipid accumulation (Kazda et al., 2016). These findings suggest a favorable safety profile and therapeutic potential for selective modulation of glucagon signaling.
Madsen et al. (2007) evaluated the stability of Glucagon (19-29) in plasma and found that the peptide exhibits enhanced resistance to proteolytic degradation relative to the native hormone, supporting its suitability for in vivo applications and as a scaffold for drug development.
Usage Guidelines and Best Practices
For research applications, Glucagon (19-29), human, should be handled and stored according to standard peptide protocols to preserve its stability and activity. The lyophilized peptide should be reconstituted in sterile water or appropriate buffer, aliquoted, and stored at -20°C or below to prevent repeated freeze-thaw cycles.
In vitro studies typically employ concentrations ranging from 10 nM to 10 μM, depending on the assay system and desired pharmacological effect. For receptor binding or signaling assays, it is recommended to include appropriate controls with full-length glucagon and vehicle to delineate the specific activity of the fragment.
In vivo studies should consider the peptide’s pharmacokinetics and potential immunogenicity. Dosing regimens should be based on prior literature and pilot studies, with careful monitoring of blood glucose, hepatic function, and other relevant endpoints. It is advisable to use validated analytical methods (e.g., LC-MS/MS, ELISA) to quantify peptide levels and assess pharmacodynamic responses.
Researchers are encouraged to consult the product datasheet (APExBIO Technology LLC, 2024) and relevant literature for detailed protocols and troubleshooting tips. Proper documentation of experimental conditions and outcomes is essential for reproducibility and data interpretation.
Future Research Directions
Several avenues for future research on Glucagon (19-29), human Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 38 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11559224